Where Does Genzyme See Alemtuzumab For MS? After Gilenya, Before Tysabri
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme laid out its strategy for getting alemtuzumab to peak sales of $3.5 billion in an effort to convince investors - and Sanofi - that it's worth more money.